WVE-007

Wave Life Sciences will present preclinical data for WVE-007 (INHBE GalNAc-siRNA) at ObesityWeek, showcasing its potential to drive fat loss while preserving muscle with infrequent dosing. Preclinical studies in DIO mice demonstrated significant weight loss, reduced visceral fat, and improved insulin sensitivity. When combined with semaglutide, weight loss doubled. Early clinical data from the INLIGHT trial show dose-dependent Activin E reductions (56-85%) that were sustained through six months. WVE-007 has shown a promising safety profile.